📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

THG shares dip on demerger plans

Published 2024-09-17, 06:54 a/m
© Reuters
THG
-

Investing.com -- Shares of THG (LON:THG) fell on Tuesday after the company said that it is reviewing potential structures to demerge THG Ingenuity.

At 6:52 am (1052 GMT), THG was trading 9.6% lower at £58.10.

The demerger would leave THG Beauty and Nutrition as standalone businesses, with Ingenuity operating independently. 

“We see this as a positive step in the long term equity story of THG,” said analysts at Barclays (LON:BARC) in a note.

While THG has secured tax clearances from HMRC, no specific timeline has been provided for the demerger. 

“From a cash perspective this would be quite substantial as close to c£80m of their c£100m capex sits in their Ingenuity business,” the analysts said


The company also reported its half year results with its THG’s Nutrition division, including its Myprotein brand, has underperformed, with revenues down 8.5% year-on-year at constant currency. 

The main drivers behind this decline include FX headwinds, particularly from the weakening Japanese Yen, and disruptions caused by the Myprotein rebrand, which led to lower-than-expected average selling prices (ASPs). 

ASPs were down 11% YoY due to the stock disruptions, although the company is optimistic about a recovery as the rebranding efforts conclude.

THG has lowered its FY24 EBITDA forecast for Nutrition, with the company now expecting to meet the lower end of consensus, at approximately £134 million, which is around 8% below market expectations.

Despite the Nutrition woes, THG’s Beauty and Ingenuity divisions provided a more optimistic outlook. Beauty revenues grew by 3.8% in the first half at constant currency, with recovery in manufacturing volumes and cost-saving measures improving EBITDA margins. 

Meanwhile, THG Ingenuity’s external revenues rose by 14.1%, though the overall division saw a 4.2% decline due to internal restructuring.

“We lower our PT by c9% from 101p to 92p after we cut our FY24 Nutrition adj. EBITDA by c14% yielding a margin of 11.5%,” Barclays said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.